Skip to main content
Research Article
Originally Published 20 April 2017
Free Access

Sugar- and Artificially Sweetened Beverages and the Risks of Incident Stroke and Dementia: A Prospective Cohort Study

Abstract

Background and Purpose—

Sugar- and artificially-sweetened beverage intake have been linked to cardiometabolic risk factors, which increase the risk of cerebrovascular disease and dementia. We examined whether sugar- or artificially sweetened beverage consumption was associated with the prospective risks of incident stroke or dementia in the community-based Framingham Heart Study Offspring cohort.

Methods—

We studied 2888 participants aged >45 years for incident stroke (mean age 62 [SD, 9] years; 45% men) and 1484 participants aged >60 years for incident dementia (mean age 69 [SD, 6] years; 46% men). Beverage intake was quantified using a food-frequency questionnaire at cohort examinations 5 (1991–1995), 6 (1995–1998), and 7 (1998–2001). We quantified recent consumption at examination 7 and cumulative consumption by averaging across examinations. Surveillance for incident events commenced at examination 7 and continued for 10 years. We observed 97 cases of incident stroke (82 ischemic) and 81 cases of incident dementia (63 consistent with Alzheimer’s disease).

Results—

After adjustments for age, sex, education (for analysis of dementia), caloric intake, diet quality, physical activity, and smoking, higher recent and higher cumulative intake of artificially sweetened soft drinks were associated with an increased risk of ischemic stroke, all-cause dementia, and Alzheimer’s disease dementia. When comparing daily cumulative intake to 0 per week (reference), the hazard ratios were 2.96 (95% confidence interval, 1.26–6.97) for ischemic stroke and 2.89 (95% confidence interval, 1.18–7.07) for Alzheimer’s disease. Sugar-sweetened beverages were not associated with stroke or dementia.

Conclusions—

Artificially sweetened soft drink consumption was associated with a higher risk of stroke and dementia.

Introduction

See related article, p 1129.
Sugar-sweetened beverages are associated with cardiometabolic diseases,1,2 which may increase the risk of stroke and dementia.3,4 Limited prior findings suggest that sugar- and artificially sweetened beverages are both associated with an increased risk of incident stroke,5 although conflicting findings have been reported.6 To our knowledge, studies are yet to examine the associations between sugary beverage consumption and the risk of incident dementia. Accordingly, we examined whether sugar- or artificially sweetened soft drinks were associated with the 10-year risks of incident stroke and dementia in the community-based Framingham Heart Study. We also examined total sugary beverages, which combined sugar-sweetened soft drinks with noncarbonated high sugar beverages, such as fruit juices and fruit drinks.

Methods

The Framingham Heart Study comprises a series of community-based prospective cohorts originating from the town of Framingham, Massachusetts. We studied the Framingham Heart Study Offspring cohort, which commenced in 1971 with the enrollment of 5124 volunteers. Participants have been studied across 9 examination cycles approximately every 4 years, with the latest cycle concluding in 2014.
We estimated the 10-year risk of both incident stroke and dementia beginning from the 7th examination cycle (1998–2001). For the study of stroke in relation to beverage intake, we excluded people with prevalent stroke or other significant neurological disease at baseline and those <45 years. For investigating the incidence of dementia, we excluded people with prevalent dementia, mild cognitive impairment, or other significant neurological disease at baseline and those <60 years. These age cutoffs are consistent with our prior work in this area.3 There were 2888 and 1484 participants available for analysis of incident stroke and new-onset dementia, respectively (Figure 1). All participants provided written informed consent, and the study procedures were approved by the Institutional Review Board at Boston University School of Medicine.
Figure 1. Selection of study participants. The risk of incident stroke and dementia were calculated as the 10-year risk, starting from examination cycle 7. Cumulative intake was calculated by averaging responses across the FFQ completed at examination cycles 5, 6, and 7 (to be included, a participant must have had examination cycle 7 data and at least one of examination cycles 5 or 6). FFQ indicates food frequency questionnaire; and MCI, mild cognitive impairment.

Assessment of Sugary Beverage Intake

Participants completed the Harvard semiquantitative food-frequency questionnaire (FFQ) at examination cycles 5 (1991–1995), 6 (1995–1998), and 7 (1998–2001). The FFQ provides a validated measure of dietary intake over the past 12 months.7 Participants responded according to how frequently they consumed 1 glass, bottle, or can of each sugary beverage item, on average, across the previous year. The FFQ included 3 items on sugar-sweetened soft drink, 4 items on fruit juice, 1 item on noncarbonated sugar-sweetened fruit drinks, and 3 items on artificially sweetened soft drinks. Each item was scored according to 9 responses spanning from never or <1 per month to 6+ per day. Intake of soft drinks using the FFQ has been validated against dietary records (correlation coefficients of 0.81 for Coke/Pepsi)8,9 and is reliable when readministered after 12 months (correlation coefficients of 0.85 for Coke/Pepsi).8,9
We combined FFQ items to create variables reflecting intake of (1) total sugary beverages (combining sugar-sweetened soft drinks, fruit juice, and fruit drinks), (2) sugar-sweetened soft drinks (high-sugar carbonated beverages, such as cola), and (3) artificially sweetened soft drinks (sugar-free carbonated beverages, such as diet cola). We created new intake categories to ensure that an adequate number of participants were retained in each intake group across each variable. Cut points were determined before conducting the main analyses based on the relative distribution of intake for each variable. Total sugary beverage consumption was examined as <1 per day (reference), 1 to 2 per day, and >2 per day; sugar-sweetened soft drink intake was examined as 0 per week (reference), ≤3 per week, and >3 per week; and artificially sweetened soft drink intake was examined as 0 per week (reference), ≤6 per week, and ≥1/d. We used FFQ data obtained from examination cycle 7 as a measure of recent intake. In an additional analysis, we also averaged responses across examination cycles 5, 6, and 7 to calculate cumulative intake over a maximum of 7 years. For this later variable, we averaged FFQ data from examination cycle 7, with FFQ data from at least 1 other examination (5 or 6). However, we averaged across all 3 examination cycles where possible (72% of participants completed all 3 FFQs; n=935 for stroke analysis sample and n=755 for dementia analysis sample).

Incident Stroke and Dementia

We related beverage consumption to the 10-year risk of stroke and dementia. Surveillance commenced from examination cycle 7 to the time of incident event over a maximum of 10 years or until last known contact with the participant. We defined stroke as the rapid onset of focal neurological symptoms of presumed vascular origin, lasting >24 hours or resulting in death. A diagnosis of dementia was made in line with the Diagnostic and Statistical Manual of Mental Disorders, 4th edition.10 A diagnosis of Alzheimer’s disease (AD) dementia was based on the criteria of the National Institute of Neurological and Communicative Disorders and Stroke and the AD and Related Disorders Association for definite, probable, or possible AD.11 Please see the online-only Data Supplement for complete details on our methods of surveillance, diagnosis, and case ascertainment.

Statistical Analysis

We used SAS software (SAS Institute, Cary, NC) to estimate Cox proportional hazards regression models (after confirming the assumption of proportionality of hazards). Recent intake and cumulative intake of total sugary beverages, sugar-sweetened soft drinks, and artificially sweetened soft drinks were related separately to the risk of all stroke, ischemic stroke, all-cause dementia, and AD dementia. Hazard ratios (HR) are presented accompanied by 95% confidence intervals (CIs).
We first performed minimally adjusted statistical models, which included adjustments for age, sex, education (for analysis of dementia only), and total caloric intake (Model 1). Next, we stepped in adjustments for lifestyle factors, including the Dietary Guidelines Adherence Index (a variable quantifying adherence to the 2005 Dietary Guidelines for Americans), as a measure of overall diet quality,12 self-reported physical activity,13 and smoking status (Model 2). A third statistical model included the adjustments outlined in Model 1, as well as additional cardiometabolic variables that may be influenced by sugary beverage intake1,2,14,15 or associated with an increased risk of stroke or dementia.3,4,16 These variables included systolic blood pressure, treatment of hypertension, prevalent cardiovascular disease, atrial fibrillation, left ventricular hypertrophy, total cholesterol, high-density lipoprotein cholesterol, prevalent diabetes mellitus, positivity for at least 1 apolipoprotein E ε4 allele (for analysis of dementia only) and waist-to-hip ratio (Model 3). All covariates were obtained from examination cycle 7. We report Models 2 and 3 as our primary analyses (please see Tables I and II in the online-only Data Supplement for Model 1 results).
We explored for interactions between beverage consumption and important confounders, including waist-to-hip ratio, apolipoprotein E ε4 allele status, and prevalent diabetes mellitus. We considered results statistically significant if a 2-sided P<0.05, except for tests of interaction which were considered statistically significant if a 2-sided P<0.1.

Sensitivity Analysis

We performed mediation analyses to examine if any of the following covariates mediated the observed associations between cumulative intake of artificially sweetened soft drink and the outcomes: prevalent hypertension, prevalent cardiovascular disease, prevalent diabetes mellitus, waist-to-hip ratio, total cholesterol, and high-density lipoprotein cholesterol.

Results

Table 1 displays cohort characteristics classified by total sugary beverage and artificially sweetened soft drink intake for the larger stroke study sample (see Table III in the online-only Data Supplement for a summary of the dementia study sample). Total caloric intake increased across categories of total sugary beverage but not artificially sweetened soft drink intake categories. The prevalence of cardiovascular disease and diabetes mellitus decreased with more frequent consumption of total sugary beverages but increased with greater consumption of artificially sweetened soft drink.
Table 1. Cohort Demographics at Examination Cycle 7 for the Stroke Study Sample (N=2888)
 Total Sugary BeveragesArtificially Sweetened Soft Drinks
<1/d1–2/d>2/d0/wk1–6/wk≥1/d
N (%)1317 (46)1103 (38)468 (16)1343 (47)1024 (35)519 (18)
Age, y61 (9)63 (9)62 (10)63 (9)63 (8)60 (8)
Male, n (%)533 (40)521 (47)248 (53)573 (43)458 (45)270 (52)
No HS degree54 (4)40 (4)14 (3)61 (5)28 (3)19 (4)
Waist/hip, ratio, median (Q1, Q3)0.95 (0.90, 1.00)0.96 (0.90, 1.01)0.96 (0.91, 1.00)0.95 (0.89, 0.99)0.96 (0.90, 1.01)0.97 (0.92, 1.02)
BMI, ratio, median (Q1, Q3)28 (25, 31)27 (24, 30)27 (24, 31)27 (24, 30)28 (25, 31)29 (26, 33)
SBP, mm Hg127 (19)128 (19)127 (18)127 (19)128 (19)127 (18)
Rx Hyp, n (%)453 (34)382 (35)148 (32)407 (30)372 (36)204 (39)
TC, mg/dL203 (37)200 (37)199 (37)203 (37)200 (37)197 (36)
HDL-C, mg/dL55 (18)54 (17)51 (15)55 (17)54 (17)52 (16)
DM, n (%)187 (15)128 (12)36 (8)94 (7)145 (15)112 (22)
AF, n (%)40 (3)57 (5)17 (4)44 (3)42 (4)28 (5)
CVD, n (%)157 (12)126 (11)45 (10)135 (10)125 (12)68 (13)
Smoker, n (%)*182 (14)114 (10)56 (12)204 (15)91 (9)57 (11)
APOE ε4, n (%)287 (22)242 (22)107 (23)286 (22)225 (22)123 (24)
PAI, units, median (Q1, Q3)36 (33, 41)37 (33, 41)37 (34, 42)37 (34, 42)37 (33, 41)36 (33, 40)
Total caloric intake, Cal/d1647 (539)1839 (548)2257 (612)1840 (608)1767 (573)1869 (590)
DGAI, units9 (3)10 (3)9 (3)9 (3)10 (3)9 (3)
Saturated fat, g/d21 (10)22 (9)25 (11)22 (10)21 (10)23 (10)
Trans fat, g/d2 (1)3 (1)3 (2)3 (1)3 (1)3 (2)
Omega-3, g/d11 (5)12 (5)13 (6)12 (6)11 (5)13 (5)
Dietary fiber, g/d17 (8)19 (7)21 (8)18 (8)18 (8)18 (7)
Alcohol, g/d11 (17)10 (14)9 (13)10 (16)10 (15)10 (15)
Mean (SD) reported unless specified otherwise. AF indicates atrial fibrillation; APOE, apolipoprotein E; BMI, body mass index; cal, calories; CVD, prevalent cardiovascular disease; DGAI, dietary guidelines adherence index; DM, diabetes mellitus; HDL-C, high-density lipoprotein cholesterol; HS, high school; PAI, physical activity index; Rx Hyp, treatment for hypertension; SBP, systolic blood pressure; and TC, total cholesterol.
*
Defined as current smoker.
Presence of at least one APOE ε4 allele. Sugar-sweetened soft drink consumption was as follows: never, 1539 (53%); ≤3 times/week, 936 (32%); ≥3 times/week, 412 (14%).

Sweetened Beverage Consumption and the Risk of Stroke

Greater recent consumption of artificially sweetened soft drink was associated with an increased risk of stroke, with the strongest associations observed for ischemic stroke (Table 2). Higher cumulative intake of artificially sweetened soft drink was also associated with an increased risk of ischemic stroke (Table 2 and Figure 2). Neither intake of total sugary beverages nor intake of sugar-sweetened soft drink was associated with the risks of stroke.
Table 2. Beverage Intake and the Risk of Stroke
 ModelRecent IntakeCumulative Intake
All StrokeIschemic StrokeAll StrokeIschemic Stroke
HR (95% CI)P ValueHR (95% CI)P ValueHR (95% CI)P ValueHR (95% CI)P Value
Total sugary beverages
 <1/d (ref)2        
 1–2/d 1.12 (0.67–1.88)0.651.06 (0.61–1.82)0.841.09 (0.65–1.81)0.750.90 (0.51–1.58)0.71
 >2/d 1.29 (0.65–2.55)0.470.86 (0.38–1.91)0.700.75 (0.33–1.69)0.490.60 (0.24–1.49)0.27
 <1/d (ref)3        
 1–2/d 1.15 (0.73–1.81)0.551.14 (0.70–1.85)0.611.22 (0.77–1.94)0.401.16 (0.70–1.92)0.58
 >2/d 1.22 (0.65–2.29)0.540.92 (0.44–1.93)0.830.88 (0.42–1.83)0.730.70 (0.30–1.65)0.41
Sugar-sweetened soft drinks
 0/wk (ref)2        
 >0–3/wk 1.15 (0.71–1.88)0.571.11 (0.65–1.89)0.721.17 (0.70–1.97)0.551.12 (0.63–1.99)0.69
 >3/wk 0.69 (0.29–1.62)0.400.69 (0.27–1.73)0.430.61 (0.25–1.49)0.280.61 (0.23–1.61)0.32
 0/wk (ref)3        
 >0–3/wk 1.22 (0.78–1.92)0.381.25 (0.76–2.04)0.381.14 (0.70–1.85)0.601.20 (0.70–2.05)0.51
 >3/wk 0.88 (0.43–1.78)0.710.84 (0.38–1.86)0.670.80 (0.38–1.67)0.550.81 (0.36–1.83)0.61
Artificially sweetened soft drinks
 0/wk (ref)2        
 >0–6/wk 2.09 (1.24–3.51)0.0052.47 (1.39–4.40)0.0021.78 (0.98–3.23)0.062.62 (1.26–5.45)0.01
 ≥1/d 1.95 (1.02–3.73)0.0452.27 (1.11–4.64)0.031.87 (0.90–3.90)0.102.96 (1.26–6.97)0.01
 0/wk (ref)3        
 >0–6/wk 1.83 (1.14–2.93)0.012.02 (1.19–3.43)0.011.59 (0.92–2.75)0.101.98 (1.03–3.78)0.01
 ≥1/d 1.97 (1.10–3.55)0.022.34 (1.24–4.45)0.011.79 (0.91–3.52)0.092.59 (1.21–5.57)0.01
Model 1 is reported in the online-only Data Supplement. Model 2 adjusts for age, sex, total caloric intake, the dietary guidelines adherence index, self-reported physical activity, and smoking status. Model 3 adjusts for age, sex, total caloric intake, systolic blood pressure, treatment of hypertension, prevalent cardiovascular disease, atrial fibrillation, left ventricular hypertrophy, total cholesterol, high-density lipoprotein cholesterol, prevalent diabetes mellitus, and waist to hip ratio. For recent intake: N/events for all strokes were 76/2225 for Model 2 and 93/2729 for Model 3. N/events for ischemic stroke were 64/2225 for Model 2 and 78/2729 for Model 3. For cumulative intake: N/events for all strokes were 70/2137 for Model 2 and 85/2598 for Model 3. N/events for ischemic stroke were 58/2137 for Model 2 and 70/2598 for Model 3. CI indicates confidence interval; and HR, hazard ratio.
Figure 2. Cumulative consumption of artificially sweetened soft drinks and event-free survival of incident (A) all stroke and (B) all-cause dementia. Green, red, and blue lines denote intake of 0/wk, >0 to 6/wk, and ≥1/d, respectively. Incidence curves are adjusted for age, sex, and total caloric intake (as well as education for dementia as an outcome).

Sweetened Beverage Consumption and the Risk of Dementia

When examining cumulative beverage consumption, daily intake of artificially sweetened soft drink was associated with an increased risk of both all-cause dementia and AD dementia in Models 1 and 2 (Table 3; Table II in the online-only Data Supplement). However, such associations were no longer significant after adjustment for the covariates outlined in Model 3. With respect to recent beverage intake, daily intake of artificially sweetened beverages was associated with an increased risk of dementia in Model 2 only. Neither total sugary beverages nor sugar-sweetened soft drink was associated with the risks of dementia.
Table 3. Beverage Intake and the Risk of Dementia
 ModelRecent IntakeCumulative Intake
All-Cause DementiaAD DementiaAll-Cause DementiaAD Dementia
HR (95% CI)P ValueHR (95% CI)P ValueHR (95% CI)P ValueHR (95% CI)P Value
Total sugary beverages
 <1/d (ref)2        
 1–2/d 0.92 (0.53–1.58)0.750.95 (0.51–1.78)0.880.72 (0.41–1.27)0.260.69 (0.35–1.33)0.26
 >2/d 1.23 (0.59–2.58)0.591.75 (0.81–3.81)0.160.59 (0.24–1.47)0.260.78 (0.31–2.01)0.61
 <1/d (ref)3        
 1–2/d 1.09 (0.67–1.76)0.731.21 (0.69–2.13)0.500.86 (0.52–1.40)0.530.89 (0.50–1.59)0.69
 >2/d 1.19 (0.58–2.44)0.631.90 (0.89–4.05)0.100.61 (0.25–1.53)0.290.92 (0.36–2.38)0.87
Sugar-sweetened soft drinks
 0/wk (ref)2        
 >0–3/wk 0.86 (0.48–1.51)0.590.91 (0.47–1.74)0.770.75 (0.42–1.33)0.320.88 (0.45–1.70)0.69
 >3/wk 1.15 (0.49–2.68)0.751.56 (0.64–3.76)0.330.82 (0.35–1.96)0.661.23 (0.50–3.06)0.65
 0/wk (ref)3        
 >0–3/wk 1.06 (0.64–1.77)0.821.11 (0.62–2.00)0.730.80 (0.48–1.33)0.390.88 (0.49–1.59)0.68
 >3/wk 0.94 (0.41–2.13)0.871.30 (0.56–3.04)0.540.77 (0.35–1.70)0.520.91 (0.37–2.24)0.84
Artificially sweetened soft drinks
 0/wk (ref)2        
 >0–6/wk 1.39 (0.79–2.43)0.251.48 (0.78–2.82)0.231.41 (0.77–2.59)0.271.68 (0.82–3.43)0.15
 ≥1/d 2.20 (1.09–4.45)0.032.53 (1.15–5.56)0.022.47 (1.15–5.30)0.022.89 (1.18–7.07)0.02
 0/wk (ref)3        
 >0–6/wk 1.00 (0.60–1.67)0.991.05 (0.59–1.87)0.871.30 (0.74–2.29)0.361.66 (0.86–3.20)0.13
 ≥1/d 1.08 (0.54–2.17)0.831.29 (0.59–2.80)0.531.70 (0.80–3.61)0.172.03 (0.83–4.97)0.12
Model 1 is reported in the online-only Data Supplement. Model 2 adjusts for age, sex, total caloric intake, education, the dietary guidelines adherence index, self-reported physical activity, and smoking status. Model 3 adjusts for age, sex, education, total caloric intake, systolic blood pressure, treatment of hypertension, prevalent cardiovascular disease, atrial fibrillation, left ventricular hypertrophy, total cholesterol, high-density lipoprotein cholesterol, prevalent diabetes mellitus, waist to hip ratio, and positivity for at least 1 APOE ε4 allele. For recent intake: N/events for all-cause dementia were 66/1135 for Model 2 and 81/1348 for Model 3. N/events for AD dementia were 52/1135 for Model 2 and 63/1348 for Model 3. For cumulative intake: N/events for all-cause dementia were 61/1087 for Model 2 and 75/1285 for Model 3. N/events for AD dementia were 47/1087 for Model 2 and 57/1285 for Model 3. APOE indicates apolipoprotein E; CI, confidence interval; and HR, hazard ratio.

Interactions

We did not observe any interactions with waist-to-hip ratio, diabetes mellitus status, or the presence of the apolipoprotein E ε4 allele with intake of any beverage examined.

Mediation Analysis

Prevalent diabetes mellitus status was identified as a potential mediator of the association between artificially sweetened beverage intake and the risk of both incident all-cause dementia and AD dementia (see Results in the online-only Data Supplement). When repeating the primary analysis excluding those with prevalent diabetes mellitus and adjusting for Model 1 covariates, daily intake of artificially sweetened beverages (versus no intake) remained a significant predictor of both incident all-cause dementia (HR, 2.45; 95% CI, 1.07–5.59; N/events, 53/1148) and AD dementia (HR, 3.23; 95% CI, 1.22–8.52; N/events, 40/1148). Thus, diabetes mellitus was a partial but not full mediator of the association between artificially sweetened beverage intake and incident dementia. Prevalent hypertension was a potential mediator of the association between artificially sweetened beverage intake and incident all-stroke, but not ischemic stroke (see Results in the online-only Data Supplement). After excluding people with prevalent hypertension, and after adjustment for Model 1 covariates, the association between artificially sweetened beverage intake and incident all-stroke was attenuated (0 per week, reference; >0–6 per week: HR, 1.53; 95% CI, 0.58–4.02; ≥1 per day: HR, 1.43; 95% CI, 0.40–5.11; N/events, 23/1456). No other mediation was identified.

Discussion

In our community-based cohort, higher consumption of artificially sweetened soft drink was associated with an increased risk of both stroke and dementia. Neither total sugary beverages nor sugar-sweetened soft drink consumption was associated with the risks of stroke or dementia.
The Nurses Health Study and Health Professionals Follow-Up Study reported that greater consumption of sugar- and artificially sweetened soft drinks was each independently associated with a higher risk of incident stroke over 28 years of follow-up for women (N=84 085) and 22 years of follow-up for men (N=43 371).5 The Northern Manhattan Study, a population-based multiethnic cohort (N=2564), reported that daily consumption of artificially sweetened soft drink was associated with a higher risk of combined vascular events but not stroke when examined as an independent outcome.6 Our study provides further evidence to link consumption of artificially sweetened beverages with the risk of stroke, particularly ischemic stroke. To our knowledge, our study is the first to report an association between daily intake of artificially sweetened soft drink and an increased risk of both all-cause dementia and dementia because of AD.
Our observation that artificially sweetened, but not sugar-sweetened, soft drink consumption was associated with an increased risk of stroke and dementia is intriguing. Sugar-sweetened beverages provide a high dose of added sugar, leading to a rapid spike in blood glucose and insulin,17 providing a plausible mechanism to link consumption to the development of stroke and dementia risk factors. Like sugar-sweetened soft drinks, artificially sweetened soft drinks are associated with risk factors for stroke and dementia,1,14,15 although the mechanisms are incompletely understood, and inconsistent findings have been reported.18
Artificially sweetened beverages are typically sweetened with non-nutritive sweeteners, such as saccharin, acesulfame, aspartame, neotame, or sucralose. At the time of FFQ administration in this study, saccharin, acesulfame-K, and aspartame were Food and Drug Administration approved, whereas sucralose was approved in 1999, neotame in 2002, and stevia in 2008.18 Collectively, these synthetic substances are much more potent than sucrose, with only trace amounts needed to generate the sensation of sweetness.17
Previous studies linking artificially sweetened beverage consumption to negative health consequences have been questioned based on concerns regarding residual confounding and reverse causality, whereby sicker individuals consume diet beverages as a means of negating a further deterioration in health.19 Indeed, in our study, diabetes mellitus—a known risk factor for dementia20—was more prevalent in those who regularly consumed artificially sweetened soft drinks. Diabetes mellitus status also partially mediated the association between artificially sweetened soft drink intake and incident dementia. Because our study was observational, we are unable to determine whether artificially sweetened soft drink intake increased the risk of incident dementia through diabetes mellitus or whether people with diabetes mellitus were simply more likely to consume diet beverages. Some studies have provided evidence for the former.21 Artificial sweeteners have been shown to cause glucose intolerance in mice by altering gut microbiota and are associated with dysbiosis and glucose intolerance in humans.21 A systematic review and meta-analysis reported that artificially sweetened beverage consumption was associated with incident diabetes mellitus, although publication bias and residual confounding were considered possible.14 Clinical trials are needed to establish whether the consumption of artificially sweetened beverages is causally related to dementia or surrogate end points, such as cognitive decline or brain atrophy.
In our study, prevalent hypertension, the single most important stroke risk factor, attenuated the association between artificially sweetened beverage intake and incident all-stroke, although not ischemic stroke. Prospective cohort studies, such as the Nurses Health Study, have demonstrated associations between higher intake of artificially sweetened beverages and an increased risk of incident hypertension.22 However, it remains unclear whether artificial sweeteners cause hypertension or whether diet beverages are favored by those most at risk. Given that clinical trials involving stroke end points are large and costly, clinical trials should investigate whether artificially sweetened beverages are associated with important stroke risk factors, such as high blood pressure.
Limitations of the study include the absence of ethnic minorities, which limits the generalizability of our findings to populations of non-European decent. Second, the observational nature of our study precludes us from inferring causal links between artificially sweetened beverage consumption and the risks of stroke and dementia. Third, the use of a self-report FFQ to obtain dietary intake data may be subject to recall bias, thus, introducing error into our estimated models. Fourth, although we addressed confounding in numerous ways, we cannot exclude the possibility of residual confounding. Finally, we did not adjust for multiple comparisons meaning that some findings may be attributable to chance.
In conclusion, artificially sweetened soft drink consumption was associated with an increased risk of stroke and dementia. Sugar-sweetened beverages were not associated with an increased risk of such outcomes. As the consumption of artificially sweetened soft drinks is increasing in the community,23 along with the prevalence of stroke24 and dementia,25 future research is needed to replicate our findings and to investigate the mechanisms underlying the reported associations.

Supplemental Material

File (str_stroke-2016-016027_supp1.pdf)

References

1.
Dhingra R, Sullivan L, Jacques PF, Wang TJ, Fox CS, Meigs JB, et al. Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community. Circulation. 2007;116:480–488. doi: 10.1161/CIRCULATIONAHA.107.689935.
2.
Fung TT, Malik V, Rexrode KM, Manson JE, Willett WC, Hu FB. Sweetened beverage consumption and risk of coronary heart disease in women. Am J Clin Nutr. 2009;89:1037–1042. doi: 10.3945/ajcn.2008.27140.
3.
Pase MP, Beiser A, Enserro D, Xanthakis V, Aparicio H, Satizabal CL, et al. Association of ideal cardiovascular health with vascular brain injury and incident dementia. Stroke. 2016;47:1201–1206. doi: 10.1161/STROKEAHA.115.012608.
4.
Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, et al.; American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke. 2011;42:2672–2713. doi: 10.1161/STR.0b013e3182299496.
5.
Bernstein AM, de Koning L, Flint AJ, Rexrode KM, Willett WC. Soda consumption and the risk of stroke in men and women. Am J Clin Nutr. 2012;95:1190–1199. doi: 10.3945/ajcn.111.030205.
6.
Gardener H, Rundek T, Markert M, Wright CB, Elkind MS, Sacco RL. Diet soft drink consumption is associated with an increased risk of vascular events in the Northern Manhattan Study. J Gen Intern Med. 2012;27:1120–1126. doi: 10.1007/s11606-011-1968-2.
7.
Rimm EB, Giovannucci EL, Stampfer MJ, Colditz GA, Litin LB, Willett WC. Reproducibility and validity of an expanded self-administered semiquantitative food frequency questionnaire among male health professionals. Am J Epidemiol. 1992;135:1114–1126, discussion 1127.
8.
Hu FB, Rimm E, Smith-Warner SA, Feskanich D, Stampfer MJ, Ascherio A, et al. Reproducibility and validity of dietary patterns assessed with a food-frequency questionnaire. Am J Clin Nutr. 1999;69:243–249.
9.
Salvini S, Hunter DJ, Sampson L, Stampfer MJ, Colditz GA, Rosner B, et al. Food-based validation of a dietary questionnaire: the effects of week-to-week variation in food consumption. Int J Epidemiol. 1989;18:858–867.
10.
American Psychatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Text revision. Arlington, VA: American Psychatric Association; 2000.
11.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939–944.
12.
Fogli-Cawley JJ, Dwyer JT, Saltzman E, McCullough ML, Troy LM, Jacques PF. The 2005 Dietary Guidelines for Americans Adherence Index: development and application. J Nutr. 2006;136:2908–2915.
13.
Kannel WB, Sorlie P. Some health benefits of physical activity. The Framingham Study. Arch Intern Med. 1979;139:857–861.
14.
Imamura F, O’Connor L, Ye Z, Mursu J, Hayashino Y, Bhupathiraju SN, et al. Consumption of sugar sweetened beverages, artificially sweetened beverages, and fruit juice and incidence of type 2 diabetes: systematic review, meta-analysis, and estimation of population attributable fraction. BMJ. 2015;351:h3576.
15.
Fowler SP, Williams K, Hazuda HP. Diet soda intake is associated with long-term increases in waist circumference in a biethnic cohort of older adults: the San Antonio Longitudinal Study of Aging. J Am Geriatr Soc. 2015;63:708–715. doi: 10.1111/jgs.13376.
16.
Wolf PA, D’Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991;22:312–318.
17.
Ludwig DS. Artificially sweetened beverages: cause for concern. JAMA. 2009;302:2477–2478. doi: 10.1001/jama.2009.1822.
18.
Gardner C, Wylie-Rosett J, Gidding SS, Steffen LM, Johnson RK, Reader D, et al.; American Heart Association Nutrition Committee of the Council on Nutrition, Physical Activity and Metabolism, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Disease in the Young, and the American D. Nonnutritive sweeteners: current use and health perspectives: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2012;126:509–519. doi: 10.1161/CIR.0b013e31825c42ee.
19.
Mattes RD, Popkin BM. Nonnutritive sweetener consumption in humans: effects on appetite and food intake and their putative mechanisms. Am J Clin Nutr. 2009;89:1–14. doi: 10.3945/ajcn.2008.26792.
20.
Chatterjee S, Peters SA, Woodward M, Mejia Arango S, Batty GD, Beckett N, et al. Type 2 diabetes as a risk factor for dementia in women compared with men: a pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia. Diabetes Care. 2016;39:300–307. doi: 10.2337/dc15-1588.
21.
Suez J, Korem T, Zeevi D, Zilberman-Schapira G, Thaiss CA, Maza O, et al. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature. 2014;514:181–186. doi: 10.1038/nature13793.
22.
Winkelmayer WC, Stampfer MJ, Willett WC, Curhan GC. Habitual caffeine intake and the risk of hypertension in women. JAMA. 2005;294:2330–2335. doi: 10.1001/jama.294.18.2330.
23.
Sylvetsky AC, Welsh JA, Brown RJ, Vos MB. Low-calorie sweetener consumption is increasing in the United States. Am J Clin Nutr. 2012;96:640–646. doi: 10.3945/ajcn.112.034751.
24.
Lee S, Shafe ACE, Cowie MR. UK Stroke Incidence, Mortality and Cardiovascular Risk Management 1999–2008: Time-trend analysis from the general practice research database. BMJ Open. 2011;1:e000269
25.
Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9:63–75.e2. doi: 10.1016/j.jalz.2012.11.007.

eLetters(0)

eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.

Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.

Information & Authors

Information

Published In

Go to Stroke
Go to Stroke

The image is taken from an article in this issue, “Intracranial Dural Arteriovenous Fistulae” by Reynolds et al (Stroke. 2017;48:1424–1431. doi: 10.1161/STROKEAHA.116.012784). The image is Figure 1.

Stroke
Pages: 1139 - 1146
PubMed: 28428346

Versions

You are viewing the most recent version of this article.

History

Received: 9 November 2016
Revision received: 15 February 2017
Accepted: 23 February 2017
Published online: 20 April 2017
Published in print: May 2017

Permissions

Request permissions for this article.

Keywords

  1. dementia
  2. Framingham Heart Study
  3. soft drinks
  4. stroke
  5. sugar

Subjects

Authors

Affiliations

Matthew P. Pase, PhD
From the Department of Neurology (M.P.P., J.J.H., A.S.B., H.J.A., C.L.S., S.S.) and Sections of Preventive Medicine and Epidemiology, Department of Medicine (R.S.V), Boston University School of Medicine, MA; Framingham Heart Study, MA (M.P.P., J.J.H., A.S.B., H.J.A., C.L.S., R.S.V., S.S., P.F.J.); Centre for Human Psychopharmacology, Swinburne University of Technology, Australia (M.P.P.); Department of Biostatistics (J.J.H., A.S.B.) and Department of Epidemiology (R.S.V.), Boston University School of Public Health, MA; and Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA (P.F.J.).
Jayandra J. Himali, PhD
From the Department of Neurology (M.P.P., J.J.H., A.S.B., H.J.A., C.L.S., S.S.) and Sections of Preventive Medicine and Epidemiology, Department of Medicine (R.S.V), Boston University School of Medicine, MA; Framingham Heart Study, MA (M.P.P., J.J.H., A.S.B., H.J.A., C.L.S., R.S.V., S.S., P.F.J.); Centre for Human Psychopharmacology, Swinburne University of Technology, Australia (M.P.P.); Department of Biostatistics (J.J.H., A.S.B.) and Department of Epidemiology (R.S.V.), Boston University School of Public Health, MA; and Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA (P.F.J.).
Alexa S. Beiser, PhD
From the Department of Neurology (M.P.P., J.J.H., A.S.B., H.J.A., C.L.S., S.S.) and Sections of Preventive Medicine and Epidemiology, Department of Medicine (R.S.V), Boston University School of Medicine, MA; Framingham Heart Study, MA (M.P.P., J.J.H., A.S.B., H.J.A., C.L.S., R.S.V., S.S., P.F.J.); Centre for Human Psychopharmacology, Swinburne University of Technology, Australia (M.P.P.); Department of Biostatistics (J.J.H., A.S.B.) and Department of Epidemiology (R.S.V.), Boston University School of Public Health, MA; and Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA (P.F.J.).
Hugo J. Aparicio, MD
From the Department of Neurology (M.P.P., J.J.H., A.S.B., H.J.A., C.L.S., S.S.) and Sections of Preventive Medicine and Epidemiology, Department of Medicine (R.S.V), Boston University School of Medicine, MA; Framingham Heart Study, MA (M.P.P., J.J.H., A.S.B., H.J.A., C.L.S., R.S.V., S.S., P.F.J.); Centre for Human Psychopharmacology, Swinburne University of Technology, Australia (M.P.P.); Department of Biostatistics (J.J.H., A.S.B.) and Department of Epidemiology (R.S.V.), Boston University School of Public Health, MA; and Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA (P.F.J.).
Claudia L. Satizabal, PhD
From the Department of Neurology (M.P.P., J.J.H., A.S.B., H.J.A., C.L.S., S.S.) and Sections of Preventive Medicine and Epidemiology, Department of Medicine (R.S.V), Boston University School of Medicine, MA; Framingham Heart Study, MA (M.P.P., J.J.H., A.S.B., H.J.A., C.L.S., R.S.V., S.S., P.F.J.); Centre for Human Psychopharmacology, Swinburne University of Technology, Australia (M.P.P.); Department of Biostatistics (J.J.H., A.S.B.) and Department of Epidemiology (R.S.V.), Boston University School of Public Health, MA; and Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA (P.F.J.).
Ramachandran S. Vasan, MD
From the Department of Neurology (M.P.P., J.J.H., A.S.B., H.J.A., C.L.S., S.S.) and Sections of Preventive Medicine and Epidemiology, Department of Medicine (R.S.V), Boston University School of Medicine, MA; Framingham Heart Study, MA (M.P.P., J.J.H., A.S.B., H.J.A., C.L.S., R.S.V., S.S., P.F.J.); Centre for Human Psychopharmacology, Swinburne University of Technology, Australia (M.P.P.); Department of Biostatistics (J.J.H., A.S.B.) and Department of Epidemiology (R.S.V.), Boston University School of Public Health, MA; and Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA (P.F.J.).
Sudha Seshadri, MD*
From the Department of Neurology (M.P.P., J.J.H., A.S.B., H.J.A., C.L.S., S.S.) and Sections of Preventive Medicine and Epidemiology, Department of Medicine (R.S.V), Boston University School of Medicine, MA; Framingham Heart Study, MA (M.P.P., J.J.H., A.S.B., H.J.A., C.L.S., R.S.V., S.S., P.F.J.); Centre for Human Psychopharmacology, Swinburne University of Technology, Australia (M.P.P.); Department of Biostatistics (J.J.H., A.S.B.) and Department of Epidemiology (R.S.V.), Boston University School of Public Health, MA; and Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA (P.F.J.).
Paul F. Jacques, DSc*
From the Department of Neurology (M.P.P., J.J.H., A.S.B., H.J.A., C.L.S., S.S.) and Sections of Preventive Medicine and Epidemiology, Department of Medicine (R.S.V), Boston University School of Medicine, MA; Framingham Heart Study, MA (M.P.P., J.J.H., A.S.B., H.J.A., C.L.S., R.S.V., S.S., P.F.J.); Centre for Human Psychopharmacology, Swinburne University of Technology, Australia (M.P.P.); Department of Biostatistics (J.J.H., A.S.B.) and Department of Epidemiology (R.S.V.), Boston University School of Public Health, MA; and Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA (P.F.J.).

Notes

*
Drs Seshadri and Jacques are joint senior authors.
The online-only Data Supplement is available with this article at http://stroke.ahajournals.org/lookup/suppl/doi:10.1161/STROKEAHA.116.016027/-/DC1.
Correspondence to Matthew P. Pase, PhD, Department of Neurology, Boston University School of Medicine & Framingham Heart Study, 72 E Concord St, Boston, MA 02118. E-mail [email protected]

Disclosures

None.

Sources of Funding

Dr Pase is funded by a National Health and Medical Research Council (APP1089698). The Framingham Heart Study is supported by the National Heart, Lung, and Blood Institute (contract no N01-HC-25195 and no HHSN268201500001I) and by grants from the National Institute on Aging (R01 AG054076, R01 AG049607, R01 AG033193, U01 AG049505, and U01 AG052409) and the National Institute of Neurological Disorders and Stroke (NS017950 and UH2 NS100605). Funds from the USDA Agricultural Research Service Agreement No. 58-1950-4-003 supported in part the collection of dietary data for this project and the efforts of Dr Jacques. Department of Medicine and Evan’s Foundation’s Evans Scholar Award to Dr Vasan.

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

  1. High consumption of artificially sweetened beverages and associated risk of cardiovascular events: A systematic review and meta-analysis, Current Problems in Cardiology, 50, 1, (102837), (2025).https://doi.org/10.1016/j.cpcardiol.2024.102837
    Crossref
  2. References, The Immune System, (471-578), (2025).https://doi.org/10.1016/B978-0-443-23565-8.09996-8
    Crossref
  3. Lifestyle Factors Affecting Biological Processes and Health, The Immune System, (99-129), (2025).https://doi.org/10.1016/B978-0-443-23565-8.00009-0
    Crossref
  4. Carbonated Beverage, Fruit Drink, and Water Consumption and Risk of Acute Stroke: the INTERSTROKE Case-Control Study, Journal of Stroke, 26, 3, (391-402), (2024).https://doi.org/10.5853/jos.2024.01543
    Crossref
  5. Prevalence and Predictors of the Use of Low-Calorie Sweeteners Among Non-Pregnant, Non-Lactating Women of Reproductive Age in Australia, Nutrients, 16, 22, (3963), (2024).https://doi.org/10.3390/nu16223963
    Crossref
  6. The Association between Dietary Protein Intake and Sources and the Rate of Longitudinal Changes in Brain Structure, Nutrients, 16, 9, (1284), (2024).https://doi.org/10.3390/nu16091284
    Crossref
  7. Artificially sweetened beverages consumption and risk of obesity-related cancers: a wide-angled Mendelian randomization study, Frontiers in Nutrition, 11, (2024).https://doi.org/10.3389/fnut.2024.1347724
    Crossref
  8. Consumption of ultra-processed foods and risk for Alzheimer’s disease: a systematic review, Frontiers in Nutrition, 10, (2024).https://doi.org/10.3389/fnut.2023.1288749
    Crossref
  9. Associations Between Beverage Consumption and Risk of Microvascular Complications Among Individuals With Type 2 Diabetes, The Journal of Clinical Endocrinology & Metabolism, (2024).https://doi.org/10.1210/clinem/dgae242
    Crossref
  10. Dietary patterns and cardiorespiratory fitness in midlife and subsequent all-cause dementia: findings from the Cooper Center Longitudinal Study, International Journal of Behavioral Nutrition and Physical Activity, 21, 1, (2024).https://doi.org/10.1186/s12966-024-01663-x
    Crossref
  11. See more
Loading...

View Options

View options

PDF and All Supplements

Download PDF and All Supplements

PDF/EPUB

View PDF/EPUB
Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to access the full text.

Purchase access to this article for 24 hours

Sugar- and Artificially Sweetened Beverages and the Risks of Incident Stroke and Dementia
Stroke
  • Vol. 48
  • No. 5

Purchase access to this journal for 24 hours

Stroke
  • Vol. 48
  • No. 5
Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

Media

Figures

Other

Tables

Share

Share

Share article link

Share

Comment Response